Simulations Plus (SLP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Simulations Plus

NasdaqGS•Healthcare•Health Information Services

$18.43+0.01(<0.01%)Market closed

Market Cap

$371.85M

P/E

45.9x

P/S

4.5x

P/B

2.7x

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.

How this company scores

GoodMetricSide Score: 73/100

Strongest: Cash & Earnings Quality (24/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability16/25

Growth18/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality24/25

Strengths

Rising free cash flowRising earningsInterest easily coveredCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 45.9x5y range 0.1x – 101.0x

Currently below its 16-quarter median.

P/S · 4.5x5y range 0.0x – 22.7x

Currently below its 20-quarter median.

P/B · 2.7x5y range 0.0x – 6.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $371.85M

Metrics at a Glance

as of May 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $82.06M
Q. Revenue: $21.89M
TTM EBITDA: $17.12M
TTM Op. Income: $11.50M
Q. Op. Income: $4.50M
TTM Net Income: $8.11M
Q. Net Income: $3.58M
EPS: $0.18
Shares Out.: $20.21M

$82.06M in TTM revenue grew 2.1% YoY, reaching $21.89M last quarter. TTM EBITDA of $17.12M and TTM operating income of $11.50M show growth is flowing through to the bottom line. TTM net income of $8.11M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 69.1%
EBITDA Margin: 26.8%
Op. Margin: 20.6%
Net Margin: 16.3%

Op. margin of 20.6% is up 385.1% YoY — cost efficiency is improving. Net margin at 16.3% and gross margin of 69.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 106% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 45.9x
P/S Ratio: 4.5x
P/B Ratio: 2.7x

At 45.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 4.5x and P/B of 2.7x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $152.98M
Cash: $35.32M
Long-Term Debt: N/A
Book Value: $139.03M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $8.71M
TTM Free Cash Flow: $24.54M
FCF Margin: 29.9%
FCF / Net Income: 3.0

TTM FCF of $24.54M on $8.71M in operating cash flow. The FCF / Net Income ratio of 3.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 6 consecutive quarters — an improving trend.